Melanoma antigens that produce cell-mediated immune responses in melanoma patients: joint U.S.-U.S.S.R. study

Science ◽  
1975 ◽  
Vol 190 (4212) ◽  
pp. 391-392 ◽  
Author(s):  
V. Gorodilova ◽  
A. Hollinshead
Keyword(s):  
Immune Responses ◽  
Produce Cell ◽  
Melanoma Antigens ◽  
Melanoma Patients

Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant

2001 ◽  
Vol 10 (3) ◽  
pp. 161-167 ◽  
Author(s):  
R. E. Hunger ◽  
C. U. Brand ◽  
M. Streit ◽  
J. A. Eriksen ◽  
M. K. Gjertsen ◽  
...  
Keyword(s):  
Immune Responses ◽  
Intradermal Injection ◽  
Gm Csf ◽  
Successful Induction ◽  
Melanoma Patients

P12 Immune responses in melanoma patients immunized with an anti-idiotype (Id) antibody mimicking GD2

1999 ◽  
Vol 9 (3) ◽  
pp. 327
Author(s):  
K. A. Foon ◽  
O. Kashala ◽  
J. Garrison ◽  
R. A. Reisfeld ◽  
A. Teitelbaum ◽  
...  
Keyword(s):  
Immune Responses ◽  
Melanoma Patients

scholarly journals STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1448 ◽  
Author(s):  
Stella Logotheti ◽  
Brigitte M. Pützer
Keyword(s):  
Immune Responses ◽  
Autoimmune Diseases ◽  
Disease Burden ◽  
Patient Management ◽  
Immune Dysregulation ◽  
Systemic Delivery ◽  
Simultaneous Management ◽  
Melanoma Patients ◽  
Targeting Strategy

Melanoma is a skin cancer which can become metastatic, drug-refractory, and lethal if managed late or inappropriately. An increasing number of melanoma patients exhibits autoimmune diseases, either as pre-existing conditions or as sequelae of immune-based anti-melanoma therapies, which complicate patient management and raise the need for more personalized treatments. STAT3 and/or STAT5 cascades are commonly activated during melanoma progression and mediate the metastatic effects of key oncogenic factors. Deactivation of these cascades enhances antitumor-immune responses, is efficient against metastatic melanoma in the preclinical setting and emerges as a promising targeting strategy, especially for patients resistant to immunotherapies. In the light of the recent realization that cancer and autoimmune diseases share common mechanisms of immune dysregulation, we suggest that the systemic delivery of STAT3 or STAT5 inhibitors could simultaneously target both, melanoma and associated autoimmune diseases, thereby decreasing the overall disease burden and improving quality of life of this patient subpopulation. Herein, we review the recent advances of STAT3 and STAT5 targeting in melanoma, explore which autoimmune diseases are causatively linked to STAT3 and/or STAT5 signaling, and propose that these patients may particularly benefit from treatment with STAT3/STAT5 inhibitors.

Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8030-8030 ◽  
Author(s):  
R. E. Hawkins ◽  
A. Dangoor ◽  
U. Keilholz ◽  
D. Schadendorf ◽  
A. Harris ◽  
...  
Keyword(s):  
Immune Responses ◽  
Metastatic Melanoma ◽  
Elispot Assay ◽  
Viral Vector ◽  
Stage Iii ◽  
High Dose ◽  
Skin Reactions ◽  
Local Skin ◽  
Tumour Control ◽  
Melanoma Patients

8030 Background: This trialevaluated the safety, immunogenicity and tumour response of increasing doses of DNA plasmid (DNA.Mel3) and MVA viral vector (MVA.Mel3), containing 7 melanoma epitopes. Methods: 41 HLA-A2 positive stage III/IV melanoma patients with unresectable measurable disease were enrolled. Immunisations were administered three weeks apart with continued MVA.Mel3 boosting in patients with tumour control. Epitope-specific CD8+ T cell responses were evaluated using ex vivo tetramer staining and interferon gamma (IFN-γ) ELISPOT assay. Results: DNA.Mel3 was well tolerated at all doses. Dose-related grade 3 local skin reactions and systemic immune-associated reactions were observed following MVA.Mel3, no reactions led to early study discontinuation. Melan-A tetramer responses were observed in 23/36 (64%) evaluable patients, of which 9/36 showed an IFNγ response to at least one epitope in ELISPOT assay. Seven patients (17%) showed tumour control (PR, MR, or SD >6 months), of which 3/7 patients had associated immune responses, including one with PR > 21 months who underwent extended MVA.Mel3 boosting. Overall median progression free survival was 9 weeks (16 weeks for immune responders). Median overall survival for the intention-to-treat population is 11.7 months with follow up of 16 patients continuing. Conclusions: High dose heterologous PrimeBoost immunisation was safe and stimulated immune responses in >50% of late stage metastatic melanoma patients treated. Tumour control was observed with some evidence of association with immune response. [Table: see text] [Table: see text]

Association of pyrexia and durable response in advanced melanoma patients treated with the combination of dabrafenib and trametinib.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19046-e19046
Author(s):  
Edward Cha ◽  
Andrea Kantor ◽  
Alain Patrick Algazi ◽  
Jimmy Hwang ◽  
Jennifer Luan ◽  
...  
Keyword(s):  
Adverse Event ◽  
Immune Responses ◽  
Common Adverse Event ◽  
Advanced Melanoma ◽  
Disease Stage ◽  
Colorectal Cancers ◽  
Braf Mutations ◽  
Durable Response ◽  
Mutation Status ◽  
Melanoma Patients

e19046 Background: Pyrexia (fever) is a common adverse event associated with combined BRAF and MEK inhibition (dabrafenib and trametinib). Although the mechanism of fever is unclear, we explore pyrexia as a pharmacodynamic marker for clinical response. Methods: A phase II international trial with dabrafenib and trametinib in metastatic melanoma (MM) and colorectal cancers (CRC) harboring BRAF mutations is ongoing. Twenty-nine patients (pts) were enrolled at UCSF between January 2011 and January 2012. Fevers were graded based on temperature and coinciding symptoms, and an episode of pyrexia was defined as a temperature of >100 °F at least once a day for one or more consecutive days. Tumor assessments were performed every 8 weeks (wks). Results: To date, 13 pts with MM and 5 with CRC had tumor assessments up to 24 wks. In MM, pyrexia was reported 2 or more times in 7 pts; 5 had none, and 1 reported one episode of Grade 1 pyrexia. Episodes occurred 2-4 wks after starting treatment, and time between subsequent recurrences ranged from 1 to 25 wks. Neutrophil counts showed early fluctuations, but none had neutropenia. Of the 7 pts with recurring fevers, 5 had partial responses and 2 had stable disease at 8 wks. Of the 6 pts with nonrecurring or no fevers, 2 had partial responses at 8 wks, and 1 progressed. At 24 wks, all 7 pts with ≥ 2 fever episodes remained progression-free, whereas 0/6 pts with < 2 fever episodes were progression-free (p < 0.001). Pts without progression continued to have recurring fevers (median = 4). There were no differences by disease stage (12 of 13 with M1c) or mutation status (10 with V600E; 2 with V600K; 1 with V600E + V601I). While pts with CRC had pyrexia, no association between pyrexia and response was noted; however, only 5 pts are included in this analysis. Conclusions: In this limited analysis of pts with MM, recurrent fevers were associated with durable response (≥ 24 wks). These results suggest that pyrexia could be a marker for inflammation and antitumor activity. Further studies are underway to characterize cytokine profiles and immune responses. [Table: see text]

scholarly journals Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

2016 ◽  
Vol 5 (7) ◽  
pp. e1191732 ◽  
Author(s):  
Steve Boudewijns ◽  
Kalijn F. Bol ◽  
Gerty Schreibelt ◽  
Harm Westdorp ◽  
Johannes C. Textor ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Immune Responses ◽  
Stage Iii ◽  
Dendritic Cell Vaccination ◽  
Melanoma Patients ◽  
Stage Iii Melanoma
Sign in / Sign up

Export Citation Format

Share Document